Latest Articles

Publication Date
Data pharmacovigilance analysis of medroxyprogesterone-related adverse events in the FDA adverse event reporting system.

Medroxyprogesterone acetate (MPA), a steroid progesterone, is widely used to treat endometriosis, menstrual disorders, and uterine bleeding in clinical practice. However, the safety profile of MPA requires comprehensive evaluation.

Published: Jan. 31, 2025, midnight
Diagnosis of Genital Tuberculosis Unveiled by Utero-Cutaneous Fistula and Superimposed MRSA Infection: A Case Report.

Both tuberculosis and Methicillin-Resistant Staphylococcus Aureus (MRSA) are known to be notorious for causing fistulas due to their characteristics of persis-tent, difficult-to-treat infections that lead to chronic inflammation, abscess formation, …

Published: Jan. 31, 2025, midnight
The NLRP3 activation-related signature predicts the diagnosis and indicates immune characteristics in endometriosis.

Endometriosis (EMS) is a prevalent gynecological disease that leads to chronic pelvic pain and infertility in women of reproductive age. However, the underlying pathogenic genes and effective treatment for EMS …

Published: Jan. 31, 2025, midnight
Decreased expression of miR-200a and miR-223-3p in endometriosis during the secretory phase of menstrual cycle: Insights from a case-control study on molecular biomarkers and disease-related infertility.

Endometriosis (EM) is a condition that causes infertility with decreasing uterine receptivity. It is reported that it affects about 20-25% of all infertile women. Some genetic markers play a crucial …

Published: Jan. 31, 2025, midnight
Ovarian cancer prevention through opportunistic salpingectomy during abdominal surgeries: A cost-effectiveness modeling study.

There is indication that the fallopian tubes might be involved in ovarian cancer pathogenesis and their removal reduces cancer risk. Hence, bilateral salpingectomy during hysterectomy or sterilization, so called opportunistic …

Published: Jan. 30, 2025, midnight
Eligibility criteria for the use menopausal hormone therapy (MHT) in women with medical conditions (II): Endometriosis, neurological and autoimmune diseases.

This project developed eligibility criteria for menopausal hormone therapy in patients with medical conditions beyond those published in a previous report. A new consortium of scientific societies coordinated by the …

Published: Jan. 30, 2025, midnight
Reproductive Endocrine Disorders: A Comprehensive Guide to the Diagnosis and Management of Infertility, Polycystic Ovary Syndrome, and Endometriosis.

Reproductive endocrine disorders, including infertility, polycystic ovary syndrome (PCOS), and endometriosis, significantly impact women's reproductive health and overall well-being. This comprehensive review explores the diagnosis and management strategies for these …

Published: Jan. 30, 2025, midnight
Investigating racial disparities in drug prescriptions for patients with endometriosis.

We assess racial disparities in medication prescription patterns for endometriosis patients across Medicaid administrative claims data. We use ATC 3rd level drug codes to identify drug classes prescribed significantly more …

Published: Jan. 30, 2025, midnight
Rare malignant ovarian tumors: a review.

There are many histologic types of gynecologic malignancies. I reviewed three rare ovarian tumor types that have poor prognoses. Ovarian mesonephric-like adenocarcinoma (MLA) is a newly described histological type known …

Published: Jan. 29, 2025, midnight
The value of MRI in differentiating ovarian clear cell carcinoma from other adnexal masses with O-RADS MRI scores of 4-5.

To assess the utility of clinical and MRI features in distinguishing ovarian clear cell carcinoma (CCC) from adnexal masses with ovarian-adnexal reporting and data system (O-RADS) MRI scores of 4-5.

Published: Jan. 29, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!